Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.

× No keyword cloud information.

6 in total

Review 1. Practical Anatomy of the Neuromuscular Junction in Health and Disease.

Authors: Hiroshi Nishimune; Kazuhiro Shigemoto
Journal: Neurol Clin Date: 2018-05 Impact factor: 3.806

Review 2. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors: Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal: Neurol Clin Date: 2018-05 Impact factor: 3.806

Review 3. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

Authors: Rebecca L Hurst; Clifton L Gooch
Journal: Curr Neurol Neurosci Rep Date: 2016-07 Impact factor: 5.081

4. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.

Authors: Silvia Bonanno; Maria Barbara Pasanisi; Rita Frangiamore; Lorenzo Maggi; Carlo Antozzi; Francesca Andreetta; Angela Campanella; Greta Brenna; Lorenzo Cottini; Renato Mantegazza
Journal: SAGE Open Med Date: 2018-12-17

Review 5. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.

Authors: Waqar Waheed; Eric Newman; Marwa Aboukhatwa; Maryam Moin; Rup Tandan
Journal: Ther Clin Risk Manag Date: 2022-07-12 Impact factor: 2.755

6. Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study.

Authors: Marco Ceccanti; Laura Libonati; Gabriele Ruffolo; Pierangelo Cifelli; Federica Moret; Vittorio Frasca; Eleonora Palma; Maurizio Inghilleri; Chiara Cambieri
Journal: Front Pharmacol Date: 2022-08-16 Impact factor: 5.988

6 in total